Literature DB >> 139696

Leucocyte ultrastructure and folate metabolism in Down's syndrome.

G S Gericke, P B Hesseling, S Brink, F C Tiedt.   

Abstract

Electron microscopical and haematological investigation of peripheral blood has shown a higher percentage of leukaemia-like nuclear ultrastructural abnormalities in the leucocytes of 30 individuals with Down's syndrome (mean 6.3%) than in normal controls (mean less than 1%). Most of these aberrations consisted of nuclear membrane abnormalities. Red cell folate values were very low in the group with Down's syndrome. Although mean serum folate and vitamin B12 levels were normal in this group, these individuals displayed increasing macrocytosis and decreasing serum folate levels with age. The whole group with Down's syndrome showed an increased mean corpuscular volume (MCV). The percentage of ultrastructural abnormalities did not correlate with folate levels when they were analysed individually. The existence of nuclear membrane abnormalities and folate deficiency, both of which may be associated with increased chromosome breakage, may be partly responsible for the increased leukaemia risk in patients with Down's syndrome.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 139696

Source DB:  PubMed          Journal:  S Afr Med J


  8 in total

Review 1.  Nuclear envelope-limited chromatin sheets (ELCS) and heterochromatin higher order structure.

Authors:  Donald E Olins; Ada L Olins
Journal:  Chromosoma       Date:  2009-06-12       Impact factor: 4.316

2.  Methotrexate sensitivity in Down's syndrome: a hypothesis.

Authors:  P M Ueland; H Refsum; B Christensen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Homocysteine and related genetic polymorphisms in Down's syndrome IQ.

Authors:  J-L Guéant; G Anello; P Bosco; R-M Guéant-Rodríguez; A Romano; C Barone; P Gérard; C Romano
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

4.  Homocysteine metabolism in children with Down syndrome: in vitro modulation.

Authors:  M Pogribna; S Melnyk; I Pogribny; A Chango; P Yi; S J James
Journal:  Am J Hum Genet       Date:  2001-06-05       Impact factor: 11.025

Review 5.  The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders.

Authors:  T Bottiglieri; K Hyland; E H Reynolds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

6.  Methylenetetrahydrofolate dehydrogenase (MTHFD) enzyme polymorphism as a maternal risk factor for trisomy 21: a clinical study.

Authors:  Daniela Neagos; Ruxandra Cretu; Andreea Tutulan-Cunita; Veronica Stoian; Laurentiu Camil Bohiltea
Journal:  J Med Life       Date:  2010 Oct-Dec

Review 7.  Systematic review and meta-analysis shows a specific micronutrient profile in people with Down Syndrome: Lower blood calcium, selenium and zinc, higher red blood cell copper and zinc, and higher salivary calcium and sodium.

Authors:  Amene Saghazadeh; Maryam Mahmoudi; Atefeh Dehghani Ashkezari; Nooshin Oliaie Rezaie; Nima Rezaei
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

Review 8.  Methylenetetrahydrofolate reductase A1298C genetic variant& risk of schizophrenia: A meta-analysis.

Authors:  Vandana Rai; Upendra Yadav; Pradeep Kumar; Sushil K Yadav; Sanjay Gupta
Journal:  Indian J Med Res       Date:  2017-04       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.